Search

Your search keyword '"Luisa Ricaurte"' showing total 42 results

Search Constraints

Start Over You searched for: Author "Luisa Ricaurte" Remove constraint Author: "Luisa Ricaurte" Topic business Remove constraint Topic: business
42 results on '"Luisa Ricaurte"'

Search Results

1. EGFR inhibitors plus bevacizumab are superior than EGFR inhibitors alone as first-line setting in advanced NSCLC with EGFR mutations and BIM deletion polymorphisms (BIM-CLICaP)

2. When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review

3. Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab

4. Characteristics and outcomes of thymomas in Latin America: results from over 10 years of experience (CLICaP-LATimus)

5. Larger Nephron Size and Nephrosclerosis Predict Progressive CKD and Mortality after Radical Nephrectomy for Tumor and Independent of Kidney Function

6. Chronic and Severe Non-Lichenoid Oral Ulcers Induced by Nivolumab – Diagnostic and Therapeutic Challenge: A Case Report

7. Kidney Structural Features from Living Donors Predict Graft Failure in the Recipient

8. A Higher Foci Density of Interstitial Fibrosis and Tubular Atrophy Predicts Progressive CKD after a Radical Nephrectomy for Tumor

9. Efficacy of Osimertinib Plus Bevacizumab In Glioblastoma Patients With Simultaneous EGFR Amplification And EGFRvIII Mutation

10. Scientific productivity and cancer-related mortality: a case study of a positive association in Colombia

11. Genotyping squamous cell lung carcinoma in Colombia (Geno1.1-CLICaP)

12. Atypical skin manifestations during immune checkpoint blockage in coronavirus disease 2019–infected patients with lung cancer

13. Mentoring as an opportunity to improve research and cancer care in Latin America (AAZPIRE project)

14. Antibiotics impair immune checkpoint inhibitor effectiveness in hispanic patients with non-small cell lung cancer (AB-CLICaP)

15. Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries

16. Requisito de mortalidad y apoyo avanzado para pacientes con cáncer con COVID-19: un modelo matemático dinámico para América Latina

17. Probable hereditary familial overlap syndrome with multiple synchronous lung tumors

18. Comprehensive review of fetal adenocarcinoma of the lung

20. Challenges and shifting paradigms in clinical trials in oncology: the case for immunological and targeted therapies

21. Human Papillomavirus Infection and Lung Cancer

22. Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib

23. Precision oncology in EGFR positive non-small cell lung cancer: breaking the 10-year barrier—a case report

24. Multigene Mutation Profiling and Clinical Characteristics of Small-Cell Lung Cancer in Never-Smokers vs. Heavy Smokers (Geno1.3-CLICaP)

25. EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP)

26. Glomerular Volume and Glomerulosclerosis at Different Depths within the Human Kidney

27. P1.12 Real World Characterization and Treatment Patterns of Patients with Thymic Carcinoma: Lessons from a Latin American Collaborative Study (CLICaP-LATimus)

28. PD2.06 EGFR Inhibitors + Bevacizumab Demonstrated Superior Efficacy Compared with EGFR Inhibitors Alone as First-line Treatment in Advanced NSCLC Patients with EGFR Mutations and BIM Deletion Polymorphisms

29. P1.10 Survival of Thymoma Is Extensive in Latin-American Patients: Results from over 10 Years of Experience (CLICaP-LATimus)

30. P2.23 Characterization of Hispanic Patients Who Experienced Hyperprogression During Treatment for Advanced NSCLC with Immunotherapy

31. P2.25 Immunotherapy at Any Line of Treatment Improves Survival in Hispanic Patients with Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC) Compared with Chemotherapy (Quijote-CLICaP)

32. EP1.15-29 Real World Characterization and Treatment of Patients with Thymic Carcinoma: Lessons from a Latin-American Study (CLICaP-LATimus)

33. EP1.04-46 Immunotherapy at Any Line Improves Survival in Hispanic Patients with Advanced Metastatic NSCLC Compared to Chemotherapy (Quijote-CLICaP)

34. P02 EGFR Amplification and Sensitizing Mutations Correlates with Survival from Erlotinib in Lung Adenocarcinoma Patients

35. P2.22 Immunotherapy-related Thrombosis: Considerations and Associated Factors in Non-small Cell Lung Cancer (NSCLC) Patients

36. PD2.03 Exploration of Factors Relating to Immune Response in Patients Treated with Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (NSCLC)

37. EP1.04-44 Exploration of Factors Relating to Paradoxical Immune Response in Patients Treated with Immune Checkpoint Inhibitors for NSCLC

38. P1.14-61 EGFR Inhibitors Plus Bevacizumab Are Superior Compared to EGFR Inhibitor Monotherapy in Advanced EGFR+ NSCLC Patients with BIM Deletions

40. Squamous cell lung cancer: genomic evolution and personalized therapy

41. Effect of immunotherapy at any line of treatment on survival in Hispanic patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP)

42. P3.01-11 Depression and Inflammation in Patients with EGFR-Mutated Non-Small Cell Lung Cancer

Catalog

Books, media, physical & digital resources